Please sign in to follow a disease.

GEJC

Clinical trials for GEJC explained in plain language.

Never miss a new study

Get alerted when new GEJC trials appear

Sign up with your email to follow new studies for GEJC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

Two-Drug combo targets HER2-Positive stomach cancer after First-Line failure

Disease control Not yet recruiting

Researchers are testing whether combining trastuzumab with retlirafusp alfa helps people with HER2-positive gastric or gastroesophageal junction cancer that has worsened after standard first-line treatment. The trial enrolls about 35 adults whose tumors test HER2 2+ or 3+. Partic…

Matched conditions: GEJC

Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control

Last updated Sep 16, 2026 00:00 UTC

GEJC

Get alerted when new GEJC trials appear

Two-Drug combo targets HER2-Positive stomach cancer after First-Line failure